


[View this email in your browser](#)

# TORAPHENE®

---

Dear Toraphene Friends and UK/European Investors,

It will soon be time! After two years of painstaking innovation and hard work we have reached some fundamental milestones for our company,



As a result we will begin preparing for our next capital raise to accelerate our innovation leadership and sales growth to ensure we continue to significantly drive the transition to a more sustainable future. Please watch this space as we will be releasing further information in due course.

If you are an eligible investor and interested in evaluating us for a potential investment please pre-register to our waitlist to be first to receive our updates.

Toraphene retains a large allocation of EIS tax relief eligible shares for UK investors which we intend to maximise in this round.

**[Register your interest! Capital at Risk](#)**

Do pass this onto your friends who may be interested!

Best Regards,

Toraphene Team

Investing in start-ups and early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. Our upcoming round will be targeted exclusively at investors who are sufficiently sophisticated to understand these risks and make their own investment decisions and those approved by our crowdfunding partner.

[Register](#)



**TORAPHENE**

*Copyright (C) 2022 Toraphene. All rights reserved.*

Our mailing address is:

Want to change how you receive these emails?  
You can [update your preferences](#) or [unsubscribe](#)